The extracorporeal lung

German medical technology firm Novalung GmbH (est. 2002) produces extracorporeal artificial lungs.

International lung specialists meeting in Schloss Haigerloch, Germany
International lung specialists meeting in Schloss Haigerloch, Germany

Acute lung failure results in a 30-40% mortality rate. Along with this, the use of conventional mechanical ventilation could result in damage to lungs and other organs, which might take years to heal.

German medical technology firm Novalung GmbH (est. 2002) produces extracorporeal artificial lungs - such as the ‘Interventional Lung Assist’ (iLA) device, which ‘breathes’ for a patient, taking the strain off diseased/damaged lungs and giving them time to recuperate.

Recently, Novalung invited about 40 leading international lung specialists to attend its first lung symposium, to discuss new treatment methods for lung failure. Clinical, economic and ethical aspects of artificial ventilation for diseased/damaged lungs were discussed, along with measures and techniques to assist their regeneration. Professor Luciano Gattinoni, intensive care specialist at Milan University, said: ‘The potential for treating lung failure has not yet been fully realised.’ This, he added, is particularly true of lung protection using extracorporeal ventilation by means of an artificial lung, still used far too little despite its obvious benefits.

Dr Stefan Fischer, of the Hanover Medical School (MHH), reported on the use of the Novalung iLA extracorporeal ventilation system for patients on the lung transplant waiting list who had gone into potentially fatal lung failure. ‘Without this technology,’ he said, ‘it is highly unlikely that those patients would have survived until a transplant could be performed.’

At Regensburg University Clinic over 130 of these artificial lungs have helped patients following acute lung failure. Professor Thomas Bein said: ‘The option of inserting cannulae into the bloodstream to connect the artificial lung must be weighed up against the risk of conventional ventilation methods.’

In preparation for the second symposium in November, three working groups were formed to prepare suggestions regarding indicators for the use of artificial lungs (e.g. acute lung failure; acute infections in chronically diseased lungs; bridging the period up to lung transplantation).

30.08.2006

Read all latest stories

Related articles

Photo

Article •

The silver anniversary of the ISICEM

The 25th International Symposium of Intensive Care and Emergency Medicine, to be held at the Congress Centre in Brussels, will see us celebrate our Silver Anniversary, when we will reflect on 25…

Photo

Article •

The 33rd International Symposium on Intensive Care and Emergency Medicine

Belgium – Last year, the annual ISICEM event attracted almost 6,000 participants from 101 countries. Its chairman, Professor Jean-Louis Vincent, from the Intensive Care Medicine Department in…

Related products

Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Clinical Chemistry

· Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
DRG Instruments – DRG:Hybrid-XL

Immunochemistry

· DRG Instruments – DRG:Hybrid-XL

DRG Instruments GmbH
Fujifilm Wako – Autokit Total Ketone Bodies Assay

Clinical Chemistry

· Fujifilm Wako – Autokit Total Ketone Bodies Assay

FUJIFILM Wako Chemicals Europe GmbH
ImageVision

Reading

medigration · ImageVision

medigration GmbH
Leonardo DR mini ll

Portable DR

OR Technology ORCA · Leonardo DR mini ll

OR Technology (Oehm und Rehbein GmbH)
Subscribe to Newsletter